#United States #New York #Levi & Korsinsky #Securities Class Action #Phreesia

Phreesia, Inc. Investors on Notice: Class Action Lawsuit Deadline Approaching

Levi & Korsinsky LLP has issued a crucial reminder to investors of Phreesia, Inc. (NYSE: PHR) concerning a looming deadline for a securities class action lawsuit. This class action focuses on a period beginning May 8, 2025, and concluding March 30, 2026, covering allegations regarding misleading statements related to the company's growth and recent acquisitions.

The Allegations Behind the Case

The alert comes in response to significant fluctuations in Phreesia's stock price, which experienced a sharp decline of approximately 27%, dropping $3.03 per share after the company revised its fiscal 2027 revenue forecast. The revenue outlook was reduced from an estimated $545-$559 million to a lower range of $510-$520 million, raising immediate concerns among investors about the stability and growth prospects of the company.

The lawsuit asserts that Phreesia's management misrepresented the durability of its growth strategies, particularly regarding the company’s acquisition of AccessOne. Initially touted as a beneficial addition that would contribute significantly to total revenues in fiscal 2027, emerging details suggested that expectations for growth were overly optimistic. Companies making promises about future revenue based on acquisitions and new product launches can face severe repercussions when they disclose changes in projected earnings.

Key Points from the Class Action

During the class period, several points have surfaced suggesting that Phreesia's management led investors to believe in a stable growth trajectory. These included:

• - Claims that Phreesia cultivated multiple robust growth levers that were purported to sustain impressive revenue increments through fiscal 2027.
• - The emphasis placed on the AccessOne acquisition, which was expected to contribute around 6.5% of the company’s total revenue.
• - Announcements regarding additional products, like MediFind and Phreesia OnCall, which were presented as essential drivers of future growth.

Throughout the lawsuit, it is alleged that Phreesia misstated or misled shareholders about the sustainability of these growth contributors—factors that investors believed would elevate the company's market position and appeal.

The Discrepancy in Growth Narratives

Despite management's assurances of a resilient pharmaceutical spend and a strong outlook, by March 30, 2026, the company acknowledged that the anticipated expenditures from pharmaceutical manufacturers for the latter half of fiscal 2027 would substantially miss prior targets. Legal claims indicate that the narrative that management presented to the market regarding projected growth was substantially disconnected from the developing realities within the company.

The lawsuit details that the anticipated revenue range adjustment reflected a worrying shift from an expected growth rate of 14-16% down to only 6-8%, raising red flags for existing and potential investors. The litigation underscores the importance of clear and honest communication regarding financial forecasts, particularly pertaining to investor confidence and market stability.

Next Steps for Affected Investors

For anyone who purchased Phreesia stock within the specified timeframe and experienced financial losses, now is the time to consider options for recovery. Investors should gather proof of their purchase records and consult with Levi & Korsinsky for a no-cost evaluation of their situation. The firm emphasizes that class actions operate on a contingency basis, ensuring no upfront costs are required.

As the deadline for potential lead plaintiff appointments approaches on July 13, 2026, it’s critical for investors to remain vigilant and proactive. Investors who sold shares post-purchase at a loss are also eligible to participate in the class action lawsuit, reinforcing that the eligibility criteria hinge on purchase dates rather than shareholding status at present.

Levi & Korsinsky continues to stand out in the field of shareholder rights litigation, having secured significant recoveries for investors and earning recognition within the industry for its commitment to transparency and equity.

For questions or further information, investors can directly contact Levi & Korsinsky at (212) 363-7500 or via email at [email protected]